Scinai Immunotherapeutics Ltd. terminated its option and license arrangements for PC111 with PinCell S.r.l. after failing to reach an extension agreement before conditions expired on August 31, 2026. The company will refocus R&D resources on its NanoAb platform and CDMO business, citing the need to preserve capital in the absence of secured grant funding for PC111. Scinai is pursuing approximately €12 million in Polish grant financing for an intradermal IL-17 psoriasis program and has committed customer orders totaling $3.1 million as of August 16, 2026. The company aims to generate approximately $5 million in CDMO revenue for 2026 while advancing systemic IL-17 bispecific programs. Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on innovative immunology therapies and operates a contract development and manufacturing organization.

Scinai Immunotherapeutics reported first-half 2026 results, achieving revenues of $949 thousand and net income of approximately $1.6 million, a reversal from the prior year's net loss of $4.1 million. The profit was driven by a $6.4 million bargain purchase gain from the February 2026 acquisition of Recipharm Israel Ltd., which expanded its contract development and manufacturing organization (CDMO) platform. Operating expenses increased due to the acquired Yavne operations, resulting in an operating loss of $4.6 million. The company secured approximately $3.1 million in committed CDMO customer orders and received $650 thousand in advances for an expanded U.S. clinical manufacturing program. Additionally, Scinai announced a one-for-ten reverse split of its American Depositary Shares (ADSs), effective August 21, 2026, increasing the ADS ratio from 4,000 to 40,000 ordinary shares per ADS. The company operates in the biopharmaceutical industry, focusing on innovative immunology therapies and providing CDMO services.

Scinai Immunotherapeutics Ltd. announced an effective change to its American Depositary Share (ADS) ratio on August 21, 2026, adjusting the conversion rate from one ADS representing 4,000 ordinary shares to one ADS representing 40,000 ordinary shares. This adjustment functions as a one-for-ten reverse split of the ADSs and is intended to increase the per-ADS trading price to regain compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per ADS. Fractional entitlements will be aggregated and sold by the depositary bank, with net proceeds distributed to holders. The company operates in the biotechnology industry, focusing on immunotherapy treatments for cancer.

Scinai Immunotherapeutics Ltd. issued a press release on June 10, 2026, detailing its first quarter 2026 financial results. The update highlighted the expansion of its Contract Development and Manufacturing Organization (CDMO) platform and progress regarding strategic growth initiatives. The company is a biotechnology firm focused on immunotherapy development and manufacturing services.

Scinai Immunotherapeutics Ltd. issued a notice to shareholders regarding a clarification in the Proxy Statement for the Annual General Meeting scheduled for June 16, 2026. The filing clarifies the expiration term of the Services Agreement for Chairman Mark Germain in relation to Proposal No. 6.